The FDA approval gives patients with multiple myeloma a second subcutaneous anti-CD38 option alongside daratumumab.

Pharmacy Times interviews Nicole McMullin, regional clinical pharmacist at American Oncology Network, on patient and caregiver education, home monitoring, multidisciplinary coordination, and key lessons for community oncology practices implementing outpatient BiTE therapy.

Learn how pharmacists secure access to new therapies with copay cards, BlinkRx pricing, and prior-authorization tips that cut delays.

The panelists examined the practical pathways available to community pharmacists who want to build their menopause expertise, with a strong consensus around the Menopause Society as a foundational starting point, offering position statements, continuing education, an annual meeting boot camp, and a certification pathway open to pharmacists, nurse practitioners, physical therapists, mental health counselors, and physicians alike.

The FDA expanded Wilate's approval for routine prophylaxis to reduce bleeding episodes in children aged younger than 6 years with von Willebrand disease, supported by phase 3 WIL-33 data showing low annualized bleeding rates and favorable tolerability.

A study published in JAMA network of opioid-naive patients with acute pain found that opioids were typically used in low doses and for short periods, but pain often lasted longer than expected and leftover medication was common.